Page last updated: 2024-11-07

gr 73632

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GR 73632: neurokinin receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119599
SCHEMBL ID2141823
MeSH IDM0186273

Synonyms (21)

Synonym
gr 73632
n-(5-amino-1-oxopentyl)-l-phenylalanyl-l-phenylalanyl-l-prolyl-n-methyl-l-leucyl-l-methioninamide
l-methioninamide, n-(5-amino-1-oxopentyl)-l-phenylalanyl-l-phenylalanyl-l-prolyl-n-methyl-l-leucyl-
gr-73632
substance p (7-10), delta-aminovaleryl-pro(9)-n-meleu(10)-
delta-aminovaleryl-9-pro-10-meleu-substance p (7-10)
substance p (7-10),delta-aminovaleryl-prolyl(9)-n-methylleucine(10)-
(2s)-n-[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-[(2s)-2-[[(2s)-2-(5-aminopentanoylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoyl]-n-methylpyrrolidine-2-carboxamide
SCHEMBL2141823
gr73632
133156-06-6
delta-aminovaleryl-phe-phe-pro-n-me-leu-met-nh2
AKOS024456737
gr 73632, >97%
DTXSID40927984
n-{2-[(5-amino-1-hydroxypentylidene)amino]-1-hydroxy-3-phenylpropylidene}phenylalanyl-n-(1-hydroxy-1-{[1-hydroxy-1-imino-4-(methylsulfanyl)butan-2-yl]imino}-4-methylpentan-2-yl)-n-methylprolinamide
HY-P1192
l-methioninamide,n-(5-amino-1-oxopentyl)-l-phenylalanyl-l-phenylalanyl-l-prolyl-n-methyl-l-leucyl-
(s)-n-((s)-1-((s)-1-amino-4-(methylthio)-1-oxobutan-2-ylamino)-4-methyl-1-oxopentan-2-yl)-1-((s)-2-((s)-2-(5-aminopentanamido)-3-phenylpropanamido)-3-phenylpropanoyl)-n-methylpyrrolidine-2-carboxamide
CS-0028937
MS-31376

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, compound 2 is predicted, based on data in preclinical species, to have a human half-life longer than 40 h and likely to have drug-drug-interactions (DDI), as 2 is a victim of CYP3A4 inhibition caused by its exclusive clearance pathway via CYP3A4 oxidation in humans."( 2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.
Ball, RG; Bao, J; Bunda, J; Chicchi, G; Cook, J; DeVita, RJ; Doss, GA; Eng, W; Gantert, L; Hargreaves, R; Hora, DF; Jiang, J; Karanam, B; Kassick, AJ; Kumar, S; Lin, P; Lu, H; Madeira, M; Mills, SG; Purcell, M; Samuel, K; Tong, X; Tsao, KL; Tschirret-Guth, R; Wang, H; Wilson, D, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Side effects of the current generation of antiemetics could potentially be reduced by improving bioavailability of the drugs in the more potent central nervous system compartment while reducing bioavailability in the less potent peripheral compartment."( Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.
Chebolu, S; Darmani, NA; Ramirez, J; Ray, AP, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Ablation of peripheral NK1 receptors attenuated the ability of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-response curve to the right."( Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Abad, J; Darmani, NA; Ramirez, J; Ray, AP; Thrush, GR; Wang, Y, 2008
)
0.35
" Pharmacokinetic (PK)/RO modeling based on the PET results predicted that once daily dosing of >30mg LY686017 led to sustained trough RO of over 80%."( Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F, 2010
)
0.36
" The antiemetic dose-response curves of tropisetron against both emetogens were U-shaped probably because larger doses of this antagonist behave as a partial agonist."( Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).
Alkam, T; Amos, B; Chebolu, S; Darmani, NA, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's44 (57.89)18.2507
2000's22 (28.95)29.6817
2010's10 (13.16)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.87 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.30%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (98.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]